SciBX: Science-Business eXchange Contents: October 10 2013, Volume 6 / Issue 39

TABLE OF CONTENTS October 10 2013, Volume 6 / Issue 39 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Cardiovascular disease Endocrine/metabolic disease Hepatic disease Infectious disease Musculoskeletal disease Neurology Pulmonary disease The Distillery: Techniques Assays and screens Computational models Disease models Drug platforms Imaging Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery Check out the latest issue of Biopharma Dealmakers, which includes the following features: - Diseases related to the immune system touch off a spectrum of valuable business models - Oncology patent cliff makes way for younger biotechs  Click here to read the issue for FREE! SciBX: Science-Business eXchange Collection on Antibiotic Resistance This special Collection from SciBX: Science-Business eXchange provides an overview of the state of affairs on antibiotic resistance from the scientific, business and regulatory perspectives.  Click here to access the Collection for free! Produced with support from: Cempra Inc., Cubist Pharmaceuticals Inc., Durata Therapeutics Inc., Polyphor Ltd.   Analysis Cover Story Top NSD2 momentum Chris Cain doi:10.1038/scibx.2013.1083 NSD2 has been genetically linked to multiple myeloma for years, but drug discovery efforts against the target have floundered. Two teams provide compelling evidence that inhibiting the protein could help treat hematological cancers. Full Text | PDF Translational Notes Top Translational tidbits Kai-Jye Lou and Lev Osherovich doi:10.1038/scibx.2013.1084 The NIH's BRAIN initiative has unveiled its near-term research priorities; research tool suppliers are starting to place bets on CRISPR-Cas9–based genome editing; a roundup of public-private partnerships shows multiple cross-national collaborations. Full Text | PDF Targets and Mechanisms Top KIM-1 driving chronic kidney disease Benjamin Boettner doi:10.1038/scibx.2013.1085 Harvard researchers have shown that KIM-1, a protein that helps overcome acute kidney injury, can also trigger chronic kidney disease. Companies modulating the target need to scrutinize the therapeutic window of their molecules. Full Text | PDF Tools Top Seeing CCR5 Tracey Baas doi:10.1038/scibx.2013.1086 A crystal structure of human CCR5 bound to the marketed HIV drug Selzentry reveals a unique binding site for the compound. The structural snapshot in combination with molecular modeling could guide future drug discovery efforts. Full Text | PDF Distillery: Therapeutics Cancer Top Solute carrier family 2 member 3 (SLC2A3; GLUT3) doi:10.1038/scibx.2013.1087 Studies in patient samples, mice and cell culture suggest targeting GLUT3 could help treat brain cancer. Full Text | PDF CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300); hypoxia-inducible factor 1α (HIF1A; HIF1α) doi:10.1038/scibx.2013.1088 In vitro and mouse studies suggest peptide inhibitors of HIF1A could help treat cancer. Full Text | PDF Integrin-linked kinase (ILK); parvin-β (PARVB) doi:10.1038/scibx.2013.1089 Mouse and cell culture studies suggest inhibiting ILK and PARVB signaling could help prevent tumor metastasis. Full Text | PDF Nuclear SET domain–containing protein 2 (NSD2; MMSET; WHSC1) doi:10.1038/scibx.2013.1090 Mouse and cell culture studies suggest inhibiting NSD2 activity could help treat t(4;14)-translocated MM. Full Text | PDF Signal transducer and activator of transcription 3 (STAT3) doi:10.1038/scibx.2013.1091 Studies in cell culture and patient samples identified STAT3 inhibitors that could help treat MM. Full Text | PDF p53 doi:10.1038/scibx.2013.1092 Studies in cell culture and patients suggest antagonizing p53 could help treat the chromosome 5q deletion (del(5q)) subtype of MDS. Full Text | PDF Fibroblast growth factor 18 (FGF18) doi:10.1038/scibx.2013.1093 Studies in patient samples and mice suggest inhibiting FGF18 signaling could help treat ovarian cancer. Full Text | PDF ADAM10; amyloid precursor protein (APP) doi:10.1038/scibx.2013.1094 Cell culture studies suggest inhibiting ADAM10 or secreted APP could increase the efficacy of Gemzar gemcitabine in pancreatic cancer. Full Text | PDF Not applicable doi:10.1038/scibx.2013.1095 In vitro and mouse studies suggest treating skin inflammation could help treat or prevent skin squamous cell carcinoma (SCC). Full Text | PDF Cardiovascular disease Top Gremlin 1 (GREM1); macrophage migration inhibitory factor (MIF) doi:10.1038/scibx.2013.1096 In vitro and mouse studies suggest a GREM1 fusion protein could be used to antagonize MIF and treat atherosclerosis. Full Text | PDF Endocrine/metabolic disease Top ATP-binding cassette sub-family A member 1 (ABCA1); microsomal triglyceride transfer protein (MTTP; MTP) doi:10.1038/scibx.2013.1097 Mouse studies suggest inhibiting MTP and ABCA1 in the intestines could help treat hypercholesterolemia and hyperlipidemia. Full Text | PDF Hepatic disease Top Proteasome activator subunit 3 (PSME3) doi:10.1038/scibx.2013.1098 Mouse studies suggest inhibition of the proteasome activator PSME3 could help treat and prevent liver steatosis. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2013.1099 Macaque studies suggest vector-based cytomegalovirus (CMV) vaccines could limit the extent of initial HIV infection and eventually eliminate it. Full Text | PDF Mycobacterium tuberculosis probable ATP-dependent protease ATP-binding subunit ClpC1 (ClpC1) doi:10.1038/scibx.2013.1100 In vitro studies identified ClpC1 as the target of antituberculosis compound cyclomarin A (CymA), which could guide the design of new ClpC1 inhibitors to treat tuberculosis. Full Text | PDF Musculoskeletal disease Top Hypoxia-inducible factor 1α (HIF1A; HIF1α) doi:10.1038/scibx.2013.1101 Mouse studies suggest HIF1A inhibitors could help prevent postmenopausal osteoporosis. Full Text | PDF Neurology Top Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB) doi:10.1038/scibx.2013.1102 Mouse studies suggest two TrkB agonists could be applied topically to treat nerve damage. Full Text | PDF Pulmonary disease Top Diacylglycerol kinase-ι (DGKI); epithelial sodium channel (ENaC) doi:10.1038/scibx.2013.1103 In vitro and cell culture studies suggest DGKI inhibition could help treat CF. Full Text | PDF Distillery: Techniques Assays and screens Top Bacterial cytological profiling (BCP) to identify the mechanism of action for antibacterial compounds doi:10.1038/scibx.2013.1104 Fluorescence imaging–based BCP can help identify the mechanism of action for antibacterial compounds. Full Text | PDF Mass spectrometry profiling of histone modifications doi:10.1038/scibx.2013.1105 Mass spectrometry profiling of histone modifications could be used to discover new cancer targets that modify chromatin. Full Text | PDF Method for expressing large genes in cardiomyocytes doi:10.1038/scibx.2013.1106 A method for expressing large genes in cardiomyocytes could be useful for creating new models and assays. Full Text | PDF Computational models Top Web-based platform to identify cancer driver mutations across tumor types based on new and existing sequencing data doi:10.1038/scibx.2013.1107 A computational model called IntOGen-mutations could help to identify mutations that drive tumor formation. Full Text | PDF Disease models Top Induced neuronal (iN) cells from mouse embryonic fibroblasts to model neurological diseases doi:10.1038/scibx.2013.1108 In vitro studies suggest iN cells could be useful for developing neurological disease models. Full Text | PDF Drug platforms Top Crystal structure of the dopamine transporter in complex with a tricyclic antidepressant doi:10.1038/scibx.2013.1109 The crystal structure of the dopamine transporter in complex with the tricyclic antidepressant nortriptyline could help guide the design of new antidepressants. Full Text | PDF Crystal structure of Selzentry maraviroc–bound HIV-1 co-receptor CC chemokine receptor 5 (CCR5; CD195) doi:10.1038/scibx.2013.1110 The crystal structure of HIV-1 co-receptor CCR5 bound by the allosteric inhibitor Selzentry maraviroc could help to guide design of therapies for HIV-1 infection. Full Text | PDF Integrated approach to accelerate biomimetic material engineering doi:10.1038/scibx.2013.1111 An integrated platform that combines RNA-seq with standard proteomics and materials science approaches could accelerate the development of new biomimetic materials. Full Text | PDF MicroRNA and small interfering RNA combination therapy for cancer doi:10.1038/scibx.2013.1112 Mouse and cell culture studies suggest combined use of miRNA and siRNA against a target could be useful for treating cancer. Full Text | PDF Protease-resistant cytotoxic antibodies doi:10.1038/scibx.2013.1113 Engineered, protease-resistant, cytotoxic, therapeutic antibodies could have better efficacy than nonresistant counterparts. Full Text | PDF Treating inflammation using mesenchymal stem cells (MSCs) overexpressing P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG), Sialyl-LewisX (SLeX) and IL-10 doi:10.1038/scibx.2013.1114 MSCs overexpressing PSGL-1, SLeX and IL-10 could be used to treat inflammation. Full Text | PDF Imaging Top Heat shock protein 90 (Hsp90) inhibitors tethered to radioiodinated or optical probes for noninvasive breast cancer imaging doi:10.1038/scibx.2013.1115 In vitro and mouse studies suggest Hsp90 inhibitors tethered to optical and radioiodinated probes could help detect and treat breast cancers. Full Text | PDF Stimulated Raman scattering (SMS) microscopy for label-free imaging of tumor-infiltrated brain tissues during surgery doi:10.1038/scibx.2013.1116 Mouse studies suggest SRS microscopy could help detect tumor margins during brain cancer surgery without using a molecular label. Full Text | PDF Top Advertisement Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer  Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.